Two investigational therapies from Assembly Biosciences have shown significant antiviral effects in early-stage clinical studies for recurrent genital herpes. The California-based company released interim data on Monday from two Phase I trials, evaluating the oral drug candidates ABI-1179 and ABI-5366.
According to Assembly’s announcement, a 50-mg dose of ABI-1179 reduced viral shedding by 98% compared to placebo over a 29-day period. This reduction surpasses the company’s prior target of 80% to 85%. The same study found that ABI-1179 lowered genital lesion rates by 91% versus placebo.
In a separate trial, ABI-5366 led to a 76% decrease in viral shedding and an 88% drop in confirmed genital lesions over the same timeframe. Samples with high viral load—a possible indicator for HSV-2 transmission—were also reduced by 81% among participants receiving the drug compared to those given placebo.
Guggenheim Partners analysts described the results as “striking,” noting in their report: “The readout strongly reinforces the greater efficacy potential of [Assembly’s] more potent, next-gen oral helicase-primase inhibitors.” After speaking with Assembly management, Guggenheim further commented: “In ABI-1179 and ABI-5366, [the company] has two strong candidates with both differentiated efficacy and more favorable dosing vs. standard of care.” The analysts suggested that ABI-1179 could offer a “potential blockbuster novel weekly treatment opportunity.”
Both therapies function by inhibiting a viral enzyme complex crucial for HSV-2 replication. According to information on Assembly’s website, this mechanism may provide “superior efficacy” over current nucleoside analog treatments used for herpes infections.
Looking ahead, Assembly intends to advance both drugs into mid-stage clinical development. A note from Mizuho Securities indicated that Phase II trials for ABI-5366 are expected to begin by mid-2026; meanwhile, plans for advancing ABI-1179 remain under consideration.
ABI-1179 was added to Assembly’s pipeline through a partnership with Gilead Sciences established in October 2023. Under this agreement, Gilead invested $100 million up front and secured options for exclusive rights over Assembly's infectious disease programs.
